ESTRO 2025 - Abstract Book

S885

Clinical - Gynaecology

ESTRO 2025

Conclusion: This study demonstrates outstanding local control (89.3%) with EBRT and HDR-BT in LACC patients, accompanied by a manageable toxicity profile. These findings underscore the potential of this combination therapy as a robust, effective, and low-morbidity treatment approach, reinforcing its value as a standard treatment option for LACC.

Keywords: HDR-BT, Locally advance cervical cancer

4427

Digital Poster Compliance with ketogenic diet in patients undergoing radiotherapy for gynaecological cancers: a prospective, randomized, mono-centric study Raffaella Michela Rinaldi 1 , Marco Cintoni 2 , Rosa Autorino 1 , Maura Campitelli 1 , Viola De Luca 1 , Valentina Chiloiro 1 , Marta Palombaro 2 , Gabriele Egidi 2 , Elena Leonardi 2 , Pauline Raoul 2 , Maria Cristina Mele 2 , Maria Antonietta Gambacorta 1 1 UOC Radioterapia Oncologica, Dipartimento di Diagnostica per immagini e Radioterapia Oncologica, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy. 2 UOC Nutrizione Clinica, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy Purpose/Objective: Recent studies have explored the Ketogenic Diet (KD) as a potentially effective strategy for maintaining muscle mass during radiotherapy (RT) for rectal cancer. This diet, characterized by a standard amount of protein, low carbohydrates, and high-fat content, may help prevent muscle loss, improve treatment tolerance, and influence cancer metabolism through the production of ketone bodies. Material/Methods: The KOMPARC study is a prospective, randomized, mono-centric trial aimed at evaluating the effects of a KD on patients undergoing radiotherapy for pelvic tumors, in particular gynaecological cancers, including endometrial and cervical carcinomas. During the initial visit, participants are randomly assigned to one of two groups: the KD group or the control group, which follows a standard diet according to ESPEN Guidelines. The KD is monitored and managed by the Clinical Nutrition Unit, with support provided to ensure adherence throughout the radiotherapy treatment period. A second visit is scheduled at the end of treatment to evaluate the results. If necessary, additional visits may occur during the therapy period. The primary endpoint of the study is to assess adherence to the dietary therapeutic plan, comparing the standard diet (SD) with the KD. Secondary endpoints include evaluating fat mass and the maintenance of metabolically active mass in the KD group versus the control group, with a particular focus on how the maintenance of body cell mass (BCM) affects metabolic, inflammatory, hematological, and endocrine responses. Additionally, safety outcomes will assess toxicities in both patient groups Results: A total of 21 patients were enrolled in the study, 10 in the intervention group (KD) and 11 in the control group between 15 June and 15 November 2024. The interruption rate of the KD was similar in both groups (KD 4 patients, 44.4% vs. SD 3 patients, 27.3%; p = 0.42). Thirteen patients completed the radiotherapy. The mean weight was maintained in both groups: 71.5 ± 19.1 kg in the KD group compared to 68.9 ± 17.3 kg in the control group, and 71.7 ± 23.2 kg versus 70.5 ± 22.6 kg, respectively. No serious adverse effects were reported in either study population.